National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedKrouse RS, Anderson GL, Arnold KB
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.
The purpose of this study was to compare surgical versus non-surgical management with the goal of determining the optimal approach for managing malignant bowel obstruction. From May 11, 2015, to April 27, 2020, 221 patients were enrolled, with 199 evaluable participants. The study found no variation between surgery and non-surgery for the primary outcome of good days: mean 42·6 days in the randomized surgery group, 43·9 days (29·5) in the randomized non-surgery group, 54·8 days (27·0) in the patient choice surgery group, and 52·7 days (30·7) in the patient choice non-surgery group. During their initial hospital stay, six participants died, five due to cancer progression and one due to malignant bowel obstruction treatment complications The most common grade 3-4 malignant bowel obstruction treatment complication was anemia.
AHRQ-funded; HS021491.
Citation: Krouse RS, Anderson GL, Arnold KB .
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.
Lancet Gastroenterol Hepatol 2023 Oct; 8(10):908-18. doi: 10.1016/s2468-1253(23)00191-7..
Keywords: Cancer, Surgery, Treatments, Comparative Effectiveness, Evidence-Based Practice
Di M, Keeney T, Belanger E
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: a population-based study.
The purpose of this study was to describe the prevalence of functional and cognitive impairments, and relationships between impairments and treatment in older patients with diffuse large B cell lymphoma (DLBCL) receiving nursing home (NH) care. The study found that of the eligible 649 NH patients 45% received chemoimmunotherapy; among the recipients, 47% received multi-agent, anthracycline-containing regimens. Those patients in a NH were less likely to receive chemoimmunotherapy, had higher 30-day mortality, and poorer OS compared with community-dwelling patients. NH patients with severe functional (61%) or any cognitive impairment (48%) were less likely to receive chemoimmunotherapy.
AHRQ-funded; HS000011.
Citation: Di M, Keeney T, Belanger E .
Functional status and therapy for older adults with diffuse large B-cell lymphoma in nursing homes: a population-based study.
J Am Geriatr Soc 2023 Jul; 71(7):2239-49. doi: 10.1111/jgs.18302..
Keywords: Elderly, Nursing Homes, Medicare, Cancer, Treatments
Carroll CE, Landrum MB, Wright AA
Adoption of innovative therapies across oncology practices-evidence from immunotherapy.
Immunotherapy has emerged as a crucial development in cancer care, significantly enhancing patient outcomes for various cancer forms, yet limited information exists regarding the adoption of this innovative treatment by different practices or the speed of uptake. The purpose of this study was to evaluate the adoption of immunotherapy across oncology practices in the United States and examine variations in adoption based on practice characteristics. This cohort investigation utilized Medicare fee-for-service data from beneficiaries undergoing six-month chemotherapy cycles between 2010 and 2017. Data analysis was conducted from January 19, 2021, to September 28, 2022, for patients diagnosed with cancers for which the US Food and Drug Administration (FDA) approved immunotherapy during the study period: melanoma, kidney cancer, lung cancer, and head and neck cancer. The primary outcome assessed whether a practice adopted immunotherapy. The data included 71,659 episodes from 1,732 oncology practices. The study found that among these, 264 practices (15%) were rural, 900 (52%) were independent, and 492 (28%) had 1 to 5 physicians. The study also found that the majority of practices adopted immunotherapy within two years of FDA approval, but considerable variations in adoption rates existed across practice types. Following FDA approval, immunotherapy adoption was 11 percentage points lower in rural practices compared to urban practices and 27 percentage points lower in practices with 1 to 5 physicians than those with six or more physicians. Adoption rates were comparable between independent practices and nonacademic institutions; however, both practice types exhibited lower adoption than academic institutions (independent practice difference, -6 percentage points; nonacademic systems difference, -9 percentage points).
AHRQ-funded; HS024072
Citation: Carroll CE, Landrum MB, Wright AA .
Adoption of innovative therapies across oncology practices-evidence from immunotherapy.
JAMA Oncol 2023 Mar;9(3):324-33. doi: 10.1001/jamaoncol.2022.6296.
Keywords: Cancer, Treatments